| Catalog No | Package | Original Price | Price | Inventory | Quantity | Operating |
|---|---|---|---|---|---|---|
| BP0201-20mg | 20mg | $36.00 | Sign in |
|
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Asarylaldehyde (CAS number: 4460-86-0) is a naturally occurring carbonyl compound with significant biological activity, which has attracted widespread attention in the field of natural product pharmacology due to its potential for various pharmacological effects. As a natural COX-2 inhibitor, Asanal exhibits potential value in anti-inflammatory and related disease treatment by specifically inhibiting cyclooxygenase II (COX-2) activity. In recent years, with the in-depth study of the molecular mechanisms of complex diseases such as pulmonary hypertension (PH), asarone has been regarded as a potential therapeutic candidate molecule due to its ability to regulate multiple key targets.
This article aims to provide a systematic review of the chemical structure and physicochemical properties, plant sources and extraction methods, pharmacological activity and mechanism of action, pharmacological evaluation and pharmacokinetic characteristics of Asanal. The focus is on exploring its molecular targets and therapeutic prospects in diseases such as pulmonary arterial hypertension, providing a theoretical basis and research direction for subsequent drug development and clinical translation.
Asanal is a typical carbonyl compound with a molecular formula of C10H12O3 and a molecular weight of 196.20. Its structure contains an aldehyde group (- CHO) and an aromatic ring, endowing it with specific chemical reactivity and biological activity. In terms of physical and chemical properties, the LogP value of Asanal is 1.3, indicating that it has moderate lipid solubility, which is beneficial for cell membrane penetration and bioavailability. Its topological polar surface area (TPSA) is 55.38 Å ² and the number of hydrogen bond acceptors is 4, indicating its hydrophilicity and binding potential in intermolecular interactions.
The blood-brain barrier penetration ability of Asanal is relatively low (BBB low permeability), which may limit its application in central nervous system diseases, but at the same time reduces the risk of central toxicity. Toxicological evaluation shows that Asanal has no significant hepatotoxicity or cardiotoxicity, and does not inhibit hERG channels, reducing the potential risk of arrhythmia. The results of Ames mutagenicity test are not yet clear, indicating the need for further genotoxicity safety evaluation.
Asarum aldehyde mainly exists in plants of the Asarum genus, especially in the volatile oils and extracts of the traditional Chinese medicine Asarum spp. As a traditional Chinese medicine, Asarum is widely used in the treatment of rheumatic pain, headache, and respiratory diseases. One of its pharmacological active ingredients is Asanal.
The common methods for extracting Asanal include steam distillation, solvent extraction, and supercritical CO2 extraction. Steam distillation is suitable for extracting the volatile oil of Asarum, but its purity is low and requires subsequent separation and purification. Solvent extraction often uses ethanol or methanol, combined with liquid chromatography (HPLC) or gas chromatography-mass spectrometry (GC-MS) for component analysis and purity control. Supercritical CO2 extraction has gradually become the preferred technology for extracting Asanal due to its strong selectivity and environmental friendliness.
In recent years, with the development of green extraction technology, ultrasound assisted extraction and microwave-assisted extraction have also been applied to the efficient extraction of Asanal, significantly improving yield and purity, providing technical support for industrial production.
The pharmacological activity of Asanal is mainly reflected in its anti-inflammatory, antioxidant, and vascular function regulation aspects. As a COX-2 inhibitor, Asanal can significantly inhibit the activity of cyclooxygenase II, with an IC50 of approximately 100 μ g/mL, exhibiting moderate selective inhibition. COX-2, as a key enzyme in inflammatory response, its inhibition helps alleviate inflammation and related pathological processes.
In animal models of pulmonary arterial hypertension, asarone improves pulmonary vascular remodeling and hemodynamic abnormalities by regulating multiple molecular targets. Related studies have shown that the targets affected by asarone include ABCB1 (ATP binding cassette transporter B1), CA12 (carbonic anhydrase 12), HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase), ACHE (acetylcholinesterase), ERN1 (endoplasmic reticulum stress sensor), KCNA5 (voltage-gated potassium channel), TGFB1 (transforming growth factor beta 1), NOS3 (endothelial nitric oxide synthase), CACNA1C (L-type calcium channel), and AGTR1 (angiotensin II receptor 1). These targets play an important role in the pathogenesis of pulmonary arterial hypertension, and the multi-target regulatory properties of asarone provide a molecular basis for its therapeutic potential.
In addition, Asanal also exhibits certain antioxidant activity, which can clear free radicals, alleviate oxidative stress damage to vascular endothelium, and further promote the recovery of vascular function.
The mechanism of action of Asanal is complex and diverse, and its pharmacological effects are mainly achieved through the following aspects:
COX-2 inhibitory effect
Asanal inhibits the catalytic synthesis of prostaglandins by binding to the active site of COX-2 enzyme, reducing the production of inflammatory mediators and alleviating inflammatory reactions. Its IC50 is 100 μ g/mL, indicating strong enzyme inhibitory activity.
Regulation of pulmonary arterial hypertension related targets
AGTR1 The angiotensin II receptor regulates vasoconstriction and blood pressure, and the antagonistic effect of asarone on AGTR1 helps to reduce pulmonary artery pressure.
Antioxidant and anti fibrotic effects
Asanal alleviates oxidative stress damage by clearing reactive oxygen species (ROS) and regulating the antioxidant enzyme system. Meanwhile, inhibiting the expression of fibrosis related factors prevents pathological thickening of the pulmonary artery wall.
In summary, Asanal exerts its potential in treating pulmonary hypertension and related diseases through multi-target and multi pathway synergistic effects.
The pharmacological parameters of Asanal indicate that it has good potential for drug development. The molecular weight is 196.2, which meets the molecular weight requirements of Lipinski rule; A LogP value of 1.3 indicates moderate lipid solubility, which is beneficial for drug absorption and distribution. The TPSA is 55.38 Å ², indicating its excellent membrane penetration ability.
In terms of safety, Asanal has no hepatotoxicity or cardiotoxicity, and does not inhibit hERG channels, reducing the risk of cardiovascular adverse reactions. The ability to penetrate the blood-brain barrier is relatively low, which may limit the application of the central nervous system, but it is beneficial for peripheral target therapy.
The pharmacokinetic study is still in its preliminary stage, and the existing data table shows that octanal is well absorbed orally, and its metabolism in vivo is mainly carried out through the liver enzyme system. The safety of the metabolites is good. In the future, further in vivo pharmacokinetic (ADME) studies of Asanal are needed, including bioavailability, half-life, tissue distribution, and excretion pathways, to guide clinical formulation design and optimize dosing regimens.
Asanal, as a natural COX-2 inhibitor, has shown broad clinical application prospects in combination with its multi-target regulatory effects on pulmonary arterial hypertension. Pulmonary arterial hypertension is a serious cardiovascular disease characterized by elevated pulmonary artery pressure and vascular remodeling. Existing treatment options are limited and have significant side effects. The multi-target mechanism of action of Asanal provides a new approach for the comprehensive treatment of pulmonary arterial hypertension.
In addition, the anti-inflammatory, antioxidant, and anti fibrotic properties of Asanal may make it potentially effective in other inflammatory diseases, cardiovascular diseases, and metabolic syndrome. Future research should focus on preclinical safety evaluation, pharmacological validation, and clinical trial design of Asanal to promote its clinical translation.
Meanwhile, based on the structural characteristics and mechanism of action of Asanal, chemical modification and drug design optimization are also worth exploring in depth to improve its biological activity and pharmacokinetic performance, and develop more clinically valuable derivatives.
As a naturally occurring carbonyl compound, Asanal exhibits excellent pharmacological activity and potential for drug development due to its significant COX-2 inhibitory activity and ability to regulate multiple targets related to pulmonary arterial hypertension. Its moderate physicochemical properties and excellent safety characteristics lay the foundation for it as a candidate molecule for new natural medicines.
In the future, combining modern pharmacology, molecular biology, and medicinal chemistry techniques to further elucidate the mechanism of action and pharmacokinetic characteristics of octanal will help promote its clinical application. Asanal not only provides an important example for the pharmacological research of natural products, but also brings new hope for the treatment of complex diseases such as pulmonary hypertension.
